Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey.
Adult
Attitude of Health Personnel
Germany
Health Care Surveys
Health Knowledge, Attitudes, Practice
Humans
Image-Guided Biopsy
/ methods
Magnetic Resonance Imaging
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Practice Patterns, Physicians'
Prostate
/ pathology
Prostatic Neoplasms
/ pathology
Urology
Germany
Internet survey
MRI targeted prostate biopsy
Multiparametric MRI
Prostate cancer
Trends
Journal
Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
03
2020
accepted:
03
05
2020
pubmed:
9
7
2020
medline:
28
5
2021
entrez:
9
7
2020
Statut:
ppublish
Résumé
Multiparametric MRI (mpMRI) and MRI targeted biopsies (MRtb) are a new standard in prostate cancer (PCa) screening and diagnosis. Guidelines already include this approach for patients at risk. We aimed to gather information from German urologists about their knowledge, routine use, and attitude toward mpMRI and consecutive biopsy methods. An anonymous online questionnaire was sent via Survey Monkey to the members of the German Society of Urology (DGU). Statistical analyses were performed using SPSS version 25.0. 496 members with a median age of 48.6 years (±11.7) participated in the survey. The majority rated mpMRI of the prostate as a very useful diagnostic tool (72.7%). MRtb of the prostate was considered as very advantageous (71.5%). MpMRI was used by 95.9%, and 83.2% also recommended MRtb predominantly in clinical institutions. For targeted biopsy, MRI-ultrasound fusion biopsy was clearly favored (75.8%). MpMRI was mostly used in patients with previously negative biopsy (90.9%) and in patients under active surveillance (60.9%). Arguments against the use of prostate mpMRI are costs (84.9%) and/or lack of sufficient radiological infrastructure (17.4%). Our data illustrate the meanwhile high acceptance and clinical use of the prostate mpMRI and MRtb in Germany.
Identifiants
pubmed: 32640460
pii: 000508755
doi: 10.1159/000508755
pmc: PMC7592851
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
731-740Informations de copyright
© 2020 The Author(s) Published by S. Karger AG, Basel.
Références
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Eur Urol. 2016 Mar;69(3):512-7
pubmed: 26112001
Urol Oncol. 2015 May;33(5):202.e1-202.e7
pubmed: 25754621
Eur Urol Focus. 2020 Mar 15;6(2):273-279
pubmed: 30219709
Cancer. 2016 Mar 15;122(6):884-92
pubmed: 26749141
Urol Oncol. 2017 Jan;35(1):32.e1-32.e7
pubmed: 27743850
AJR Am J Roentgenol. 2018 Jan;210(1):101-107
pubmed: 29064758
Nat Rev Urol. 2020 Jan;17(1):41-61
pubmed: 31316185
Eur Urol. 2019 Aug;76(2):142-150
pubmed: 31092338
CA Cancer J Clin. 2015 Nov-Dec;65(6):457-80
pubmed: 26375877
Urol Int. 2019;102(1):20-26
pubmed: 30149386
Eur Urol. 2015 Dec;68(6):1045-53
pubmed: 25656808
Curr Urol. 2019 Mar 8;12(2):97-103
pubmed: 31114467
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Urol Int. 2018;101(1):56-64
pubmed: 29734177
Urol Int. 2020;104(3-4):187-198
pubmed: 31825927
Urol Oncol. 2015 Jul;33(7):329.e7-11
pubmed: 25957713
Z Gastroenterol. 2013 Aug;51(8):753-854
pubmed: 23955142
Urol Oncol. 2014 Jan;32(1):45.e17-22
pubmed: 24055430
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Eur Urol. 2020 Mar;77(3):311-317
pubmed: 31708295
Eur Urol. 2015 Jul;68(1):8-19
pubmed: 25454618
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Eur Urol. 2018 Jan;73(1):23-30
pubmed: 28935163
Prostate Cancer Prostatic Dis. 2015 Sep;18(3):221-8
pubmed: 25986915
Eur Urol. 2017 Apr;71(4):517-531
pubmed: 27568655